Erlotinib(continued)
▶Cobicistatis predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
▶Combined hormonal contraceptivesslightly increase the
exposure toerlotinib. Monitor side effects and adjust dose.
oStudy
▶Corticosteroidsincrease the risk of gastrointestinal
perforation when given witherlotinib.rTheoretical
▶Erlotinibincreases the anticoagulant effect ofcoumarins.
rAnecdotal
▶Crizotinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Efavirenzis predicted to decrease the exposure toerlotinib.
rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
erlotinib. Avoid or adjusterlotinibdose.rStudy
▶Grapefruit juiceis predicted to increase the exposure to
erlotinib.oTheoretical
▶H 2 receptor antagonistsare predicted to decrease the exposure
toerlotinib.Erlotinibshould be taken 2 hours before or
10 hours afterH 2 receptor antagonists.oStudy
▶HIV-protease inhibitorsare predicted to slightly increase the
exposure toerlotinib. Use with caution and adjust dose.
oStudy
▶Idelalisibis predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
▶Imatinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Lapatinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Macrolides(azithromycin, erythromycin)are predicted to
increase the exposure toerlotinib.oTheoretical
▶Macrolides(clarithromycin)are predicted to slightly increase
the exposure toerlotinib. Use with caution and adjust dose.
oStudy
▶Mitotaneis predicted to decrease the exposure toerlotinib.
Avoid or adjusterlotinibdose.rStudy
▶Netupitantis predicted to increase the exposure toerlotinib.
oTheoretical
▶Nevirapineis predicted to decrease the exposure toerlotinib.
rTheoretical
▶Nilotinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Erlotinibis predicted to increase the risk of gastrointestinal
perforation when given withNSAIDs.rTheoretical
▶Erlotinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Proton pump inhibitorsare predicted to slightly decrease the
exposure toerlotinib. Avoid.oStudy
▶Quinolones(ciprofloxacin)slightly increase the exposure to
erlotinib. Monitor side effects and adjust dose.oStudy
▶Ranolazineis predicted to increase the exposure toerlotinib.
oTheoretical
▶Rifampicinis predicted to decrease the exposure toerlotinib.
Avoid or adjusterlotinibdose.rStudy
▶SSRIs(fluvoxamine)are predicted to increase the exposure to
erlotinib. Monitor side effects and adjust dose.o
Theoretical
▶St John’s Wortis predicted to decrease the exposure to
erlotinib.rTheoretical
▶Vemurafenibis predicted to increase the exposure toerlotinib.
oTheoretical
Ertapenem→see carbapenems
Erythromycin→see macrolides
Escitalopram→see SSRIs
Eslicarbazepine→see antiepileptics
Esmolol→see beta blockers, selective
Esomeprazole→see proton pump inhibitors
Estramustine→see alkylating agents
Etanercept
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
etanercept. Public Health England advises avoid (refer to
Green Book).rTheoreticalEtelcalcetide
▶Cinacalcetincreases the risk of hypocalcaemia when given
withetelcalcetide. Avoid.rTheoretical
Ethambutol
▶Isoniazidincreases the risk of optic neuropathy when given
withethambutol.rAnecdotal
Ethosuximide→see antiepileptics
Etodolac→see NSAIDs
Etomidate→seeTABLE 8p. 848 (hypotension),TABLE 11p. 849 (CNS
depressant effects)
Etonogestrel
▶Antiepileptics(carbamazepine, eslicarbazepine, fosphenytoin,
oxcarbazepine, perampanel, phenobarbital, phenytoin,
primidone, rufinamide, topiramate)are predicted to decrease
the efficacy ofetonogestrel. For FSRH guidance, see
Contraceptives, interactionsp. 497.rTheoretical
▶Aprepitantis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Bosentanis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Efavirenzis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Fosaprepitantis predicted to decrease the efficacy of
etonogestrel. For FSRH guidance, seeContraceptives,
interactionsp. 497.rTheoretical
▶Griseofulvindecreases the efficacy ofetonogestrel. For FSRH
guidance, seeContraceptives, interactionsp. 497.r
Anecdotal
▶HIV-protease inhibitors(ritonavir)are predicted to decrease the
efficacy ofetonogestrel. For FSRH guidance, see
Contraceptives, interactionsp. 497.rTheoretical
▶Modafinilis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Nevirapineis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Rifabutinis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Rifampicinis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶St John’s Wortis predicted to decrease the efficacy of
etonogestrel. MHRA advises avoid. For FSRH guidance, see
Contraceptives, interactionsp. 497.rTheoretical
▶Sugammadexis predicted to decrease the efficacy of
etonogestrel. Use additional contraceptive precautions.r
Theoretical
▶Ulipristalis predicted to decrease the efficacy ofetonogestrel.
Avoid.rTheoretical
Etoposide→seeTABLE 15p. 850 (myelosuppression)
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the efficacy of
etoposide.oStudy
▶Ciclosporinincreases the exposure toetoposide. Monitor and
adjust dose.rStudy
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
etoposide. Public Health England advises avoid (refer to Green
Book).rTheoretical
Etoricoxib→see NSAIDs
Etravirine
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toetravirine. Avoid.rTheoretical
▶Etravirinedecreases the exposure toantimalarials(artemether).
oStudy
▶Etravirineis predicted to decrease the exposure tobedaquiline.
Avoid.rTheoretical
▶Bosentanis predicted to decrease the exposure toetravirine.
Avoid.rStudy920 Erlotinib—Etravirine BNFC 2018 – 2019
Interactions|Appendix 1A1